Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine
Latest Information Update: 18 Apr 2022
Price :
$35 *
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Intestinal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Mar 2022 Status changed from active, no longer recruiting to discontinued due to low accrual.
- 25 Jan 2020 Results assessing safety and efficacy of avelumab in small bowel adenocarcinoma presented at the 2020 Gastrointestinal Cancers Symposium
- 19 Aug 2019 Status changed from recruiting to active, no longer recruiting.